STOCK TITAN

BIOXYTRAN INC - BIXT STOCK NEWS

Welcome to our dedicated page for BIOXYTRAN news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on BIOXYTRAN stock.

Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because of a limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.

Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT) received Investigational New Drug (IND) authorization from India’s CDSCO to evaluate ProLectin-I for treating Long COVID and Idiopathic Pulmonary Fibrosis (IPF). This IND complements a previous authorization for ProLectin-M. ProLectin-I could address a significant health challenge, with Long COVID affecting 65-100 million globally and an estimated economic cost of $3.7 trillion in the U.S. alone. IPF impacts about 3 million people worldwide. The drug targets viral persistence associated with Long COVID and lung fibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary

Bioxytran, Inc. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will discuss the company's participation in the Emerging Growth Conference on January 25, 2023, at 10:50 am EST. The conference will feature presentations by public companies across various growth sectors, focusing on innovative products and long-term growth potential. Investors are encouraged to preregister for attendance, and an archived webcast will be available post-event. Bioxytran is a clinical-stage biotechnology firm developing therapies for COVID-19 and other diseases, with its lead candidate being Prolectin-M, aimed at treating significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
-
Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT) announced positive outcomes from its Phase 2 clinical trial for ProLectin-M, a treatment for COVID-19. The trial achieved a 100% response rate by day 7 in 34 patients, significantly outperforming the placebo (6%). Additionally, the company received an IND letter from India's CDSCO to optimize dosage for a planned 408 patient Phase III trial. An Indian subsidiary has been established to commercialize ProLectin-M upon approval, utilizing an FDA-approved manufacturing plant aimed at the 1.4 billion population in India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
covid-19
Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT) announces the establishment of its Indian subsidiary, Pharmalectin India Private Limited, aimed at launching ProLectin-M upon receiving CDSCO approval. The FDA-approved facility is positioned to cater to India's vast market of 1.4 billion. Currently, the company has not secured a distributor for its products. ProLectin-M, Bioxytran's leading drug candidate, targets viral diseases and shows promise in treating unmet medical needs. Further details can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.17%
Tags
none
-
Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will present the latest clinical trial results at the Emerging Growth Conference on December 14, 2022, from 1:45pm to 2:45pm EST. The conference aims to showcase public companies like Bioxytran, which is developing oral and intravenous therapies for COVID-19 and other viral diseases. Interested investors are encouraged to preregister to attend the conference and access updates. Archived webcasts will also be available for those unable to attend live.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Bioxytran, Inc. (BIXT) has received Investigational New Drug (IND) authorization from India's Central Drugs Standard Control Organization (CDSCO) to optimize dosage in COVID-19 patients. This approval paves the way for a future Phase III trial involving 408 patients, aimed at refining treatment strategies for COVID-19 and other viral diseases. Bioxytran focuses on developing oral and intravenous drugs targeting significant unmet medical needs, particularly with their leading drug candidate, ProLectin-M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
covid-19
Rhea-AI Summary

BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotech firm, has announced that Avise Analytics has reinitiated coverage of its stock, setting a fair valuation at $2.71 per share. The report highlights Bioxytran's ProLectin-M, which shows promising recovery rates for Covid-19 patients and targets a multi-billion-dollar market. Additionally, the company is advancing BXT-25 for stroke treatment, addressing the critical treatment window challenge. Despite positive developments, funding limitations could impact drug development timelines. More details can be found in the full report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
none
-
Rhea-AI Summary

Bioxytran, Inc. (OTCQB: BIXT) announced positive results from its Phase 2 clinical trial involving a Galectin Antagonist for treating COVID-19. The study showed complete elimination of viral load in 100% of patients by day 7, compared to only 6% in the placebo group (p=.001). Additionally, 88% reached this result by day 3. There were no serious adverse events, and no viral rebounds were observed within 14 days. The trial supports plans for a Phase 2/3 registrational study and showcases the drug's novel mechanism of action against viral entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.5%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Bioxytran announced that its Scientific Advisor, Prof. Avraham Mayevsky, published a book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score. This work is linked to Bioxytran’s Hypoxia platform technology, which utilizes the MDX Viewer for measuring tissue oxygenation. The technology aims to enhance drug development by providing real-time data on oxygen consumption in tissues, potentially revolutionizing clinical trials. Bioxytran is focusing on its leading drug, ProLectin-M, targeting unmet medical needs in virology and hypoxia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Bioxytran, a clinical stage biotechnology company, announced a peer-reviewed article supporting its oral antiviral drug, ProLectin-M, published in the International Journal of Health Sciences. The article outlines the drug's mechanism of action (MOA) as a galectin-3 antagonist, confirming initial clinical data showing viral load reduction to undetectable levels in COVID-19 patients. ProLectin-M targets the SARS-CoV-2 virus and demonstrates promising preclinical results with non-toxic levels in humans. Bioxytran aims to address significant unmet medical needs in virology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
none

FAQ

What is the current stock price of BIOXYTRAN (BIXT)?

The current stock price of BIOXYTRAN (BIXT) is $0.088 as of December 24, 2024.

What is the market cap of BIOXYTRAN (BIXT)?

The market cap of BIOXYTRAN (BIXT) is approximately 8.1M.

What is the focus of Bioxytran, Inc.?

Bioxytran, Inc. focuses on developing therapeutic drugs to address hypoxia in humans.

What is the lead pharmaceutical drug candidate of the company?

The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule for treating brain ischemia.

What is BXT-252?

BXT-252 is an injectable anti-necrosis drug to treat wounds with limited oxygen supply.

When was Bioxytran, Inc. founded?

The company was founded in 2017.

Where is Bioxytran, Inc. headquartered?

Bioxytran, Inc. is headquartered in Newton, Massachusetts.

What are the contact details for Investor Relations at Bioxytran, Inc.?

For Investor Relations, contact Michael Sheikh at 509-991-0245 or email mike.sheikh@bioxytraninc.com.

What recent achievement has Bioxytran, Inc. made in lesion clearance and regression of Herpes Zoster Neuralgia?

The company achieved 50% lesion clearance and regression of Herpes Zoster Neuralgia within 48-72 hours.

What does the company's patent cover?

The company's patent covers a method of treating a viral infection with a lectin-binding carbohydrate. Google Patent link: https://patents.google.com/patent/WO2023178228A1/en.

What products are included in Bioxytran, Inc.'s portfolio?

The company's products include BXT-25 and BXT-252 for the treatment of various conditions related to hypoxia.

What kind of therapeutic drugs does Bioxytran, Inc. manufacture?

Bioxytran, Inc. manufactures therapeutic drugs to address the issue of hypoxia in humans.

BIOXYTRAN INC

OTC:BIXT

BIXT Rankings

BIXT Stock Data

8.15M
61.96M
26.67%
Biotechnology
Healthcare
Link
United States of America
Needham